Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
July 28, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July ...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
May 09, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 ...
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
April 27, 2022 13:43 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
April 25, 2022 09:20 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting
April 19, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., April 19, 2022 ...
Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease
March 16, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce...
Clarus Therapeutics Announces $15 Million Private Placement
December 03, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus)...
Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
November 30, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to...
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
October 26, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
December 07, 2020 09:00 ET
|
Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...